Natalizumab ( DrugBank: Natalizumab )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	159
15	封入体筋炎	1
25	進行性多巣性白質脳症	4
46	悪性関節リウマチ	2
96	クローン病	9

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 10 of 159 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05701423 (ClinicalTrials.gov)	February 8, 2023	18/1/2023	A Study of End of Dose Phenomena in Subcutaneous NatalizumabTreated Multiple Sclerosis (MS) Particip ...	End of Dose Phenomena in Subcutaneous Natalizumab Treated MS Patients	Multiple Sclerosis	Drug: Natalizumab	Biogen	NULL	Recruiting	18 Years	N/A	All	100		Germany
2	NCT05418010 (ClinicalTrials.gov)	December 1, 2022	17/2/2022	Natalizumabfor the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclero ...	AttackMS: Natalizumabfor the Treatment of People With Inflammatory Demyelination Suggestive of Multi ...	Multiple Sclerosis;Clinically Isolated Syndrome of Demyelination	Drug: Tysabri Injectable Product;Drug: Placebo	Queen Mary University of London	Biogen;UCL Queen Square Institute of Neurology;Moorfields Eye Hospital NHS Foundation Trust;Barts & ...	Recruiting	18 Years	45 Years	All	40	Phase 2	United Kingdom
3	NCT05532163 (ClinicalTrials.gov)	November 1, 2022	5/9/2022	A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous ...	A Prospective, Multicenter, Interventional, Open-Label, Single-arm Phase IV Study Over 24 Weeks to I ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab	Biogen	NULL	Not yet recruiting	18 Years	60 Years	All	40	Phase 4	NULL
4	NCT05177718 (ClinicalTrials.gov)	September 16, 2022	13/12/2021	Natalizumab and Chronic Inflammation	Assessing the Effect of Natalizumabof Magnetic Resonance Imaging Measures of Blood Brain Barrier Per ...	Multiple Sclerosis	Drug: Natalizumab 300 MG in 15 ML Injection	Vanderbilt University Medical Center	Biogen	Recruiting	18 Years	65 Years	All	36	Phase 4	United States
5	JPRN-jRCT2051210146	24/05/2022	26/12/2021	Phase 3 Study to Evaluate Efficacy, Safety, PK, and PD of SC Natalizumabin Japanese Participants Wit ...	A Single-Arm, Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Phar ...	Relapsing-Remitting Multiple Sclerosis	Participants will receive natalizumab 300 mg SC Q4W for 48 weeks.	Amir Hadi Maghzi	NULL	Recruiting	>= 18age old	<= 65age old	Both	20	Phase 3	Japan
6	NCT05304520 (ClinicalTrials.gov)	October 12, 2021	22/3/2022	A Study for Tysabri Participant Preference	SISTER - Subcutaneous: Non-Interventional Study for Tysabri Patient Preference - Experience From Rea ...	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: Natalizumab	Biogen	NULL	Recruiting	18 Years	N/A	All	500		Germany
7	NCT05688436 (ClinicalTrials.gov)	September 24, 2021	9/1/2023	A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate	Pregnancy Outcomes in Women Exposed to Diroximel Fumarate	Multiple Sclerosis	Drug: Diroximel Fumarate;Biological: Alemtuzumab;Drug: Fingolimod;Drug: Glatiramer acetate;Biologica ...	Biogen	NULL	Recruiting	18 Years	49 Years	Female	825		United States
8	NCT04964700 (ClinicalTrials.gov)	May 6, 2021	27/5/2021	Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab	Analysis of Multiple Sclerosis Patients Who Have Had Greater Than 60 Infusions of Natalizumab: Safet ...	Multiple Sclerosis	Drug: Natalizumab	Multiple Sclerosis Center of Northeastern New York	NULL	Active, not recruiting	18 Years	N/A	All	42		United States
9	NCT04580381 (ClinicalTrials.gov)	September 1, 2020	2/10/2020	Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort	Real World Effectiveness of NatalizumabExtended Interval Dosing in Relapsing-Remitting Multiple Scle ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab Injection [Tysabri]	University Hospital, Caen	Biogen	Completed	18 Years	N/A	All	500		France
10	EUCTR2019-003127-38-NL (EUCTR)	09/04/2020	09/04/2020	Research on the effect of add-on high dosage simvastatin treatment on progression in MS patients tre ...	Efficacy of add-on high dose simvastatin on markers for disease progression in MS patients treated w ...	Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Simvastatin INN or Proposed INN: SIMVASTATIN Other descriptive name: Simvastatine	VUmc Neurology Department	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	Netherlands

First Previous1 2 3 4 5…16Next Last

先頭へ

15. 封入体筋炎

臨床試験数 : 42 / 薬物数 : 33 - (DrugBank : 11) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 123

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02483845 (ClinicalTrials.gov)	May 2013	31/5/2013	Natalizumab in Inclusion Body Myositis (IBM)	Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis	Inclusion Body Myositis (IBM)	Drug: Natalizumab	Phoenix Neurological Associates, LTD	NULL	Active, not recruiting	21 Years	85 Years	All	6	Phase 1	United States

First Previous1Next Last

25. 進行性多巣性白質脳症

臨床試験数 : 26 / 薬物数 : 35 - (DrugBank : 22) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05236777 (ClinicalTrials.gov)	January 1, 2019	2/2/2022	TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportun ...	Long-term Surveillance of Patients With Multiple Sclerosis to Report Progressive Multifocal Leukoenc ...	Multiple Sclerosis	Drug: Natalizumab	Biogen	Association for Functional Rehabilitation, Recreation and Applied Kinesiology Impulse	Recruiting	N/A	N/A	All	600		Czechia
2	NCT01970410 (ClinicalTrials.gov)	October 2013	22/10/2013	MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV	MAIN STUDY: Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumabat Risk for Prog ...	Multiple Sclerosis	Drug: teriflunomide	Providence Health & Services	Multiple Sclerosis Center of Northeastern New York	Completed	21 Years	60 Years	All	55	Phase 4	United States
3	EUCTR2010-020369-26-DE (EUCTR)	29/11/2010	18/08/2010	High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Pr ...	High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Pr ...	Immune Reconstitution Inflammatory Syndrome MedDRA version: 12.1;Level: PT;Classification code 10054 ...	Product Name: methylprednisolone INN or Proposed INN: METHYLPREDNISOLONE Product Name: prednisolone INN ...	Biogen Idec	NULL	Not Recruiting			Female: yes Male: yes	20		Germany
4	NCT01211665 (ClinicalTrials.gov)	September 2010	29/7/2010	Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)	High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Pr ...	Immune Reconstitution Inflammatory Syndrome;Leukoencephalopathy, Progressive Multifocal	Drug: Methylprednisolone;Drug: Prednisolone	Biogen	Elan Pharmaceuticals	Terminated	18 Years	N/A	All	3	Phase 4	United States;Germany

First Previous1Next Last

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00831649 (ClinicalTrials.gov)	September 2004	27/1/2009	A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of In ...	A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of In ...	Rheumatoid Arthritis	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Terminated	18 Years	75 Years	Both		Phase 2	NULL
2	NCT00083759 (ClinicalTrials.gov)	May 2004	1/6/2004	Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate	A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerab ...	Rheumatoid Arthritis	Drug: natalizumab;Drug: placebo	Biogen	Elan Pharmaceuticals	Terminated	18 Years	75 Years	All	299	Phase 2	United States;Canada

First Previous1Next Last

96. クローン病

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00801125 (ClinicalTrials.gov)	December 2008	1/12/2008	Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-a Therapy	A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-a Therapy	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Withdrawn	18 Years	N/A	Both	0	Phase 4	NULL
2	NCT00707512 (ClinicalTrials.gov)	June 2008	27/6/2008	CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring	INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring	Crohn's Disease	Drug: natalizumab	Biogen	NULL	Terminated	18 Years	N/A	Both	87	N/A	United States;Puerto Rico
3	EUCTR2004-003839-31-DK (EUCTR)	05/02/2005	17/05/2005	A Phase III, Multicenter, Open-Label, Long-Term Study of the Tolerability of Intravenous Natalizumab ...	A Phase III, Multicenter, Open-Label, Long-Term Study of the Tolerability of Intravenous Natalizumab ...	Crohn's Disease (CD)	Product Name: natalizumab Product Code: AN100226 INN or Proposed INN: natalizumab	Elan Pharma Ltd.	NULL	Not Recruiting			Female: yes Male: yes	1000	Phase 3	Denmark
4	NCT00078611 (ClinicalTrials.gov)	March 2004	1/3/2004	A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease	A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intra ...	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	18 Years	N/A	Both	462	Phase 3	United States;Canada
5	NCT00280956 (ClinicalTrials.gov)	July 2002	21/1/2006	Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease	A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of I ...	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	18 Years	N/A	Both	2000	Phase 4	United States
6	NCT00055536 (ClinicalTrials.gov)	April 2002	4/3/2003	Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease	A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Ef ...	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	18 Years	N/A	Both	60	Phase 2	United States
7	NCT00055367 (ClinicalTrials.gov)	April 2002	26/2/2003	Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease	A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectivene ...	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	12 Years	17 Years	Both	30	Phase 2	United States;United Kingdom
8	NCT00032786 (ClinicalTrials.gov)	March 2002	3/4/2002	Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease	A Phase 3, International, Multicenter, Double-blind, Placebo-controlled Study of the Efficacy, Safet ...	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	18 Years	N/A	Both		Phase 3	NULL
9	NCT00032799 (ClinicalTrials.gov)	December 2001	3/4/2002	Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease	A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy ...	Crohn's Disease	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Completed	18 Years	N/A	Both	905	Phase 3	United States

First Previous1Next Last

先頭へ